Doing business with integrity
Integrity is key at Vifor Pharma. We are highly committed to it in everything we do. There is no room for unethical behaviour. We have identified two focus areas within the Responsibility pillar INTEGRITY.
Focus area: Business Behaviour
Vifor Pharma operates in a highly-regulated field. As patients’ lives are at stake, we are under intense scrutiny from the authorities and society. Working actively against any form of bribery and corruption, we have put measures in place to fight any misconduct and to protect our employees and stakeholders.
Measures include:
- Anti-bribery, anti-corruption: An ‘Anti-Bribery and Anti-Corruption Directive‘ (ABAC Directive) sets the global standards on how the company conducts business. It applies to all employees of Vifor Pharma Group. Employees are regularly trained on the ABAC Directive.
- Speaking up: A whistle-blower hotline gives employees an anonymous platform to voice concerns. In addition, an internal ‘Misconduct Reporting Policy’ outlines the process in cases of suspected misconduct, and sets out the principle of anti-retaliation.
- Compliance training: Vifor Pharma regularly trains its employees on a variety of compliance-sensitive topics. Trainings are mandatory for all employees.
(For more information, check out our latest ‘Responsibility Highlights Report 2017’)
Focus area: Transparency
We acknowledge that stakeholders have an interest in knowing whom we engage with and believe the best way to build mutual trust is to be transparent. We are therefore disclosing our relationships to stakeholders and providing means of access to information and data.
Measures include:
- Disclosure of payments and contributions: Vifor Pharma discloses payments and contributions to healthcare professionals and organisations according to applicable law and relevant provisions (e.g. EFPIA Disclosure Code). Payments and contributions are made available on our website.
- Clinical trial results data: Vifor Pharma publishes information on its clinical research in accordance with the ‘Principles for Responsible Clinical Trial Data Sharing’ issued by the European and U.S. pharmaceutical industry bodies.
(For more information, check out our latest ‘Responsibility Highlights Report 2017’)
LINKS
DOWNLOADS